Multifunctional 1,10-phenanthroline derivative and its metal complexes as an anti-Alzheimer’s agent: structure-based drug design, synthesis, characterization and pharmacological studies

Metal-based compounds containing selenium: An appealing approach towards novel therapeutic drugs with anticancer and antimicrobial effects

“…Therefore, in recent years a plethora of studies support the use of metal-based complexes as potential drugs with a wide range of pharmacological properties, such as anticancer [24][25][26], antimicrobial [27][28][29], antiparasitic [30][31][32], anti-neurodegenerative [33][34][35], or antidiabetic [36][37][38] activities.…”

“…Recently, cadmium (Cd) complexes bearing selenazoyl-hydrazones (33)(34)(35) in Fig. 3) as anticancer agents were reported, along with their S analogs for comparison [111].…”

Recent updates in the development of small molecules as potential clinical candidates for Alzheimer's disease: A review

“…Zhou et al (2018) developed a series of 2‐aryl‐9‐methyl‐β‐carbolinium bromides for anti‐AChE activity with IC 50 values in the range of 0.11–0.76 μM, higher than standard drug galantamine and high selectivity toward AChE. 1,10‐phenanthroline derivative was synthesized by group Gladis et al (2020), and AChE inhibitory effect was examined. The synthesized ligands showed selective inhibition against AChE and BuChE with IC 50 values of 0.20 and 3.20 μM as compared to references, galantamine and rivastigmine.…”